C07K 14/523
Beta-chemokines
Official title: {Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2}
C07K14/523 (Beta-chemokines) appears on 279 US grants and 309 published applications in this corpus.
Search patents in C07K- Granted patents
- 279
- Published applications
- 309
- Assignees
- 200
- Inventors
- 633
- Latest grant
- 23 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1986 | 1 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 1 | 0 |
| 1993 | 2 | 0 |
| 1994 | 3 | 0 |
| 1995 | 3 | 0 |
| 1996 | 5 | 0 |
| 1997 | 11 | 0 |
| 1998 | 14 | 0 |
| 1999 | 22 | 0 |
| 2000 | 24 | 0 |
| 2001 | 10 | 2 |
| 2002 | 17 | 25 |
| 2003 | 12 | 33 |
| 2004 | 19 | 12 |
| 2005 | 9 | 19 |
| 2006 | 14 | 20 |
| 2007 | 10 | 17 |
| 2008 | 12 | 12 |
| 2009 | 4 | 14 |
| 2010 | 11 | 8 |
| 2011 | 5 | 12 |
| 2012 | 8 | 10 |
| 2013 | 4 | 11 |
| 2014 | 5 | 11 |
| 2015 | 9 | 5 |
| 2016 | 3 | 6 |
| 2017 | 2 | 5 |
| 2018 | 5 | 11 |
| 2019 | 3 | 6 |
| 2020 | 11 | 5 |
| 2021 | 5 | 7 |
| 2022 | 3 | 10 |
| 2023 | 2 | 10 |
| 2024 | 2 | 12 |
| 2025 | 3 | 14 |
| 2026 | 4 | 12 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Heterodimeric human IgG1 polypeptides with isoelectric point modifications23 Jun 2026US 12,662,553 B2Xencor, Inc.
- Engineered MCP and PCP proteins and systems and methods thereof26 May 2026US 12,637,493 B2Trustees of Boston University
- Heterodimeric human IgG1 polypeptides with isoelectric point modifications5 May 2026US 12,617,872 B2Xencor, Inc.
- Chemokine responsive activated natural killer cells with secondary homing activation for verified targets3 Feb 2026US 12,540,170 B2ImmunityBio, Inc.
- Heterodimeric human IgG1 polypeptides with isoelectric point modifications11 Nov 2025US 12,466,897 B2Xencor, Inc.
- Anticancer agent, pharmaceutical composition for cancer treatment, kit, and activator20 Aug 2026US 2026/0240929 A1BioComo Incorporation
- Immune cell-derived secretome20 Aug 2026US 2026/0243757 A1Agency for Science, Technology and Research
- Compositions and methods of using nitration resistant ccl2 chemokines18 Jun 2026US 2026/0166126 A1Board of Regents, The University of Texas System
- Fusokines involving cytokines with strongly reduced receptor binding affinities18 Jun 2026US 2026/0167687 A1Centre Hospitalier Regional Universitaire De Montpellier
- Use of ccl1111 Jun 2026US 2026/0159563 A1Newish Technology (Beijing) Co., Ltd.
Most cited
By later US patents
- Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)104US 4,603,106 AThe Rockefeller University · 1986
- Bispecific antibody and chemokine receptor constructs97US 6,723,538 B2Micromet AG · 2004
- Assays and therapeutic methods based on lymphocyte chemoattractants88US 5,514,555 ACenter for Blood Research, Inc. · 1996
- Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)72US 4,822,776 AThe Rockefeller University · 1989
- Human CTLA-8 and uses of CTLA-8-related proteins69US 6,043,344 AGenetics Institute, Inc. · 2000